Brought to you by 
Boehringer Ingelheim, NeuroSearch develop CNS drug
04 Jun 2009
Executive Summary
In its largest deal to date, Danish biotech company NeuroSearch (central nervous system therapeutics) has licensed Boehringer Ingelheim development and marketing rights to its drug candidate NS2330, a small-molecule neurotransmitter enhancer to treat Alzheimer's and Parkinson's diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Boehringer Ingelheim, NeuroSearch develop CNS drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice